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Mucopolysaccharidoses (MPS) are a group of inherited metabolic disorders caused by deficiency of 
enzymes that degrade glycosaminoglycans (GAGs). Urinary excretion of GAGs is a common feature 
of MPS, and is considered their major biomarker. We aimed to adapt the GAG electrophoresis method 
to a commercial agarose gel which would be able to separate urinary GAGs in a simpler way with good 
sensitivity and reproducibility. Urine samples from patients previously diagnosed with MPS I, IV, and 
VI were used as electrophoretic standards. Samples from patients on enzyme replacement therapy (ERT) 
were also assessed. Commercial agarose gel electrophoresis was effective, showing proper definition 
and separation of GAG bands. Detection sensitivity exceeded 0.1 µg and band reproducibility were 
consistent. GAG bands quantified in urine samples from patients on ERT correlated very strongly 
(correlation coefficient = 0.98) with total GAG concentrations. This application of gel electrophoresis 
demonstrates the possibility of monitoring patients with MPS treated with ERT by analyzing separately 
the GAGs excreted in urine. We suggest this process should be applied to MPS screening as well as to 
follow-up of patients on treatment.
Uniterms: Mucopolysaccharidoses/tests/treatment. Electrophoresis/monitoring method. 
Glycosaminoglycans/use.
INTRODUCTION
Mucopolysaccharidoses (MPS) are a group of 
inherited metabolic disorders caused by a deficiency of 
enzymes needed for the degradation of glycosaminoglycans 
(GAGs). The intralysosomal accumulation of GAG 
molecules results in cell, tissue, and organ dysfunction, 
which involves multiple systems and follows a chronic 
and progressive course (Clarke et al., 2012).
Recently, several research groups have been 
developing methods for the analysis of urinary GAG 
levels as a tool to be used in the diagnosis and follow-up 
of MPS treatment through enzyme replacement therapy 
(ERT), which is currently available for MPS I, II, and VI 
(Aurays-Blais et al., 2011). This treatment has brought 
new perspectives to patients, as it can slow the progression 
of the disease by correcting the enzyme deficiency and, 
therefore, reducing GAG accumulation. The best results 
for ERT are obtained when it is introduced in the first years 
of the patient’s life, or in milder variants of MPS.
Among several techniques described in the 
literature, electrophoresis is widely used for separation 
and identification of different types of accumulated GAGs 
in patients’ urine. This method is known for its good 
sensitivity, reproducibility, and ease of applicability in 
laboratories, as it does not require high-cost equipment. 
In addition, agarose gel electrophoresis provides good 
visualization and definition of GAG bands (Coppa et al., 
2012).
The main objective of this study was to adapt the 
conventional technique of GAG electrophoresis to a 
commercially available agarose gel (manufactured by 
CELM) and assess the ability of this adapted method to 
separate GAGs with good visualization while maintaining 
sensitivity and band reproducibility.
MATERIAL AND METHODS
This study was approved by the Federal University 
of Rio Grande do Sul Research Ethics Committee (CAAE: 
A. C. Breier, J. Cé, J. C. Coelho694
07137612.7.0000.5347), and all participants provided 
informed consent.
Samples
Urine samples (n=8 per group) collected from 
patients with MPS I, IV, VI, and normal controls, aged 1 
to 5 years, were used as standards for the electrophoretic 
procedure. 
GAGs
GAGs were extracted from urine samples based 
on the procedure described by Di Ferrante and Rich 
(1956), which uses the principle of acid precipitation 
with cetylpyridinium chloride (CPC) as reagent. The 
technique described by De Jong, Wevers and Sambeek 
(1992) was used for total urinary GAG measurement 
using 1,9-dimethylmethylene blue (DMB), a colorimetric 
method based on the affinity of DMB dye for the sulfate 
group of GAG molecules.
Electrophoresis
Electrophoresis was performed according to the 
principles of Cappelletti, Rosso, and Chiarugi (1979) and 
Hopwood and Harrison (1982). The solid matrix selected 
for the procedure was a commercially available, ready-
to-use 0.9% agarose gel (Geral®, CELM – Companhia 
Equipadora de Laboratórios Modernos, Barueri, SP, Brazil). 
Before sample loading, the gel was set for 2 min with 0.30 
M barium acetate buffer (pH 5). For this solid matrix, the 
electrophoresis run times had to be adjusted, which made 
the technique faster. Run times and other parameters are 
presented in Table I. The electrophoresis was performed in 
0.30 M barium acetate buffer (pH 5) and developed in the 
precipitation stages with ethanol and toluidine blue dye, 
followed by destaining in water and air-drying. 
GAG standard curves and electrophoresis of 
patients on ERT
Chondroitin sulfate (CS) and dermatan sulfate 
(DS) solutions at concentrations of 0.25, 0.5, 1, and 2 
mg/mL were loaded on the commercial agarose gel and 
GAG electrophoresis was performed using the protocol 
described in Table I. Each curve was obtained in different 
gels and days, and trials were repeated three times. 
Bands were quantified in AlphaEase FC software (Alpha 
Innotech Corporation, San Leandro, CA). The results were 
expressed as mean ± standard deviation and differences 
in band quantification were analyzed using one-way 
ANOVA, with significance accepted at p<0.0001.
Urine samples from a patient on ERT treated with 
Aldurazyme® (iduronidase) for MPS I and from two 
other patients treated with Naglazyme® (galsulfase) for 
MPS VI were analyzed. GAG bands quantification results 
were compared to total urinary GAG measurements by 
Pearson’s correlation.
Quantification of electrophoretic bands
Bands stained with toluidine blue were scanned and 
quantified in AlphaEase FC software. The results of GAG 
bands were quantified in AVG (sum of total pixels divided 
by band size area) and expressed accordingly.
RESULTS
Commercial agarose gel electrophoresis
Commercial agarose gel electrophoresis was 
effective, showing proper definition and separation of 
GAG bands. The GAG accumulation patterns observed 
were in accordance with the literature: DS, HS, and CS 
bands in MPS I; KS band in MPS IV; and DS and CS 
bands in MPS VI. Healthy controls did not show any 
accumulated GAG bands. This electrophoresis technique, 
adapted to a commercially available solid gel matrix, 
showed appropriate GAG migration with excellent 
separation and visualization of bands (Figure 1).
CS and DS curves
The sensitivity and reproducibility of the commercial 
agarose gel electrophoresis technique were demonstrated 
through GAG standard curves obtained with 0.25, 0.5, 1.0, 
and 2.0 mg/mL solutions. This technique was sensitive 
and able to detect very small quantities (>0.1 µg) of 
GAGs. Three independent trials were carried out for 
TABLE I - Steps of electrophoresis technique with commercial 
agarose gel
Sample volume 0.5 µL
1st run, 5-7 min Stop and precipitation in 50% ethanol, 
5 min
2nd run, 20-35 min Stop and precipitation in 35% ethanol, 
5 min
3th run, 40-50 min Staining with 1% toluidine blue, 10 min
Destaining 20-30 min in water
Voltage constant at 100 V, current 10-20 mA
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both the CS (y=58.86x + 1.19) and DS (y=89.60x + 
10.89) curves (Figure 2a). Reproducibility was analyzed 
through quantification of bands. Staining intensities were 
significantly different (p<0.0001, one-way ANOVA).
Follow-up of patients on ERT and quantification
Figure 1b shows electrophoresis of urine samples 
from patients with MPS and the pattern of the accumulated 
GAGs bands over time (before and 6 and 12 months after 
ERT initiation).
The accumulated GAG bands visualized in the 
commercial agarose gel were quantified individually in 
AlphaEase FC software, and the total sum was compared 
to total GAG measurements in urine carried out using the 
DMB method. The Pearson correlation coefficient between 
the sum of GAG electrophoretic bands quantification 
(AVG) and the total GAG measurement was strong and 
significant at r = 0.98 (y=0.43x + 7.15) (Figure 2b).
Individual analysis of each accumulated band 
enabled visualization of DS, HS, and CS accumulation 
in MPS I and DS and CS accumulation in MPS VI, 
throughout treatment, as well as their differences over 
time.
DISCUSSION
In the present study, the principles of electrophoretic 
techniques described in the literature were adapted to a 
commercial agarose gel, yielding good results in terms 
of GAG band separation and definition. This can be 
explained by the small thickness of the gel, which allows 
faster migration of GAG molecules through the matrix 
and reduces procedure time. Additionally, reproducibility 
FIGURE 1 - Electrophoresis in a commercial agarose gel (Geral®, CELM). a) Electrophoresis run showing all GAG bands. 
KS = keratan sulfate, CS = chondroitin sulfate, HS = heparan sulfate, DS = dermatan sulfate. S = standard, C = control sample. 
b) Electrophoresis of an MPS I patient before and after enzyme replacement therapy (ERT). c) Electrophoresis of an MPS VI 
patient before and after ERT. m = months.
FIGURE 2 – a) Electrophoretic curve of CS and DS. Electrophoresis performed with different concentrations of CS and DS (0.25, 
0.5, 1.0, and 2.0 mg/mL), sample volume 0.5 µl. Analysis of CS and DS quantification curves was performed in by AlphaEase FC 
software (AVG) and calculated as mean ± standard deviation. Three independent curves were plotted for each GAG. b) Pearson 
correlation between AVG and DMB methods for GAG quantification. y = 0.43x + 7.15 and r = 0.98.
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was demonstrated through CS and DS curves. Another 
important aspect of this protocol is the short total runtime; 
due to the quicker electrophoretic runs and destaining 
procedure, results are obtained in a few hours.
Def in i t ive  d iagnosis  of  MPS can only  be 
accomplished through enzyme analysis. However, 
examining all 11 deficient enzymes in every suspected 
case is infeasible, because the tests used to measure 
enzyme activity require high-cost substrates (Reuser et 
al., 2011). Screening through urinary GAG measurement 
is ideal, as all MPS variants feature GAG accumulation, 
but quantification of total accumulated GAGs alone is 
not enough to establish MPS type. Therefore, specific 
techniques are needed for individual evaluation of the 
accumulated GAG profile in order to direct enzyme 
analysis. On the basis of our findings, we suggest that 
agarose gel electrophoresis using a commercially available 
gel matrix could be used for neonatal MPS screening 
through analysis of urinary GAGs. The electrophoretic 
profile of GAGs separated by electrophoresis has 
been applied as a screening tool to identify MPS, with 
satisfactory results (De Lima, Baccarin, Michelacci, 
2007; Gallegos-Arreola et al., 2000; Piraud et al., 1993). 
Electrophoretic analysis can also rule out suspicion of 
MPS, as our results indicate that healthy individuals do 
not accumulate GAGs through visible bands.
Urinary GAG measurement is also used for 
treatment follow-up of patients with MPS, whether treated 
with ERT or hematopoietic stem cell transplantation, given 
the importance of GAGs as biomarkers (Aurays-Blais et 
al., 2011; Wynn et al., 2009). This field has been widely 
explored and total GAG analyses have been replaced by 
methods that directly explore the individual detection of 
accumulated substrates. Liquid chromatography, ELISA, 
and mass spectrometry are examples of techniques that 
have already been evaluated for the direct quantification 
of DS and HS as a treatment follow-up method (Aurays-
Blais et al., 2011; De Ru et al., 2013). In this sense, the 
electrophoresis technique with commercial agarose gel 
presented in this study is simple and can be used in small 
laboratories. In the present study, an individual profile of 
each accumulated GAG in patients on ERT was obtained. 
After quantification, differences in GAG accumulation 
from patient to patient were observed. This is consistent 
with the literature, as the decrease in GAG accumulation in 
response to ERT depends on the type of mutation involved, 
the age at diagnosis and therapy initiation, the presence 
of neutralizing antibodies, and GAG accumulation 
status itself (Wynn et al., 2009). Thus, another suggested 
application for the method described herein is follow-up 
of patients treated with ERT by monitoring urinary GAG 
levels through commercial agarose gel electrophoresis. 
In conclusion, our adaptation of established 
electrophoresis techniques to a commercial agarose gel 
made this process simpler and faster while ensuring 
reproducibility and sensitivity. Besides separating and 
identifying accumulated GAGs in urine samples from 
MPS patients, GAG bands could be quantified for 
evaluation of response to ERT. We suggest that this simple, 
accessible, and reliable methodology can be adopted by 
clinical laboratories for neonatal screening of MPS among 
high-risk populations and for follow-up of MPS patients 
on ERT.
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